Semnur Q2 2026: $39k Cash, Going Concern Warning, and a $100M Lifeline Term Sheet
SMNR has more than doubled off its 52-week low of $0.25 on light trading volume (0.2× avg).
Summary
Semnur's Q2 2026 10-Q reveals a near-empty treasury ($39k cash), a going concern warning, and a binding term sheet for a $100M investment at $10.00/share — a potential lifeline at a huge premium to the $0.75 stock price.
Key Events · Earnings and Guidance · SMNR
-
Cash Position Near Zero
Cash and cash equivalents fell to $39,000 as of June 30, 2026, down from $20,000 at year-end 2025. The company burned $4.8 million in operations during H1 2026.
-
Going Concern Warning Reiterated
Management again expresses substantial doubt about the company's ability to continue as a going concern, citing recurring losses, negative cash flows, and dependence on parent Scilex for funding.
-
$100M Investment Term Sheet Signed
On July 3, 2026, Semnur entered a binding term sheet with iHolding Group LLP for a $100 million equity investment at $10.00 per share — a more than 12x premium to the current $0.75 stock price. The deal is subject to due diligence and definitive agreements, with no fixed completion date.
-
Prior Financing Deals Terminated
In April 2026, Semnur terminated both the $20 million PIPE SPA and the $100 million Semnur/Biconomy SPA, eliminating $120 million in previously announced financing.
Analysis · SMNR · Life Sciences
With just $39,000 in cash at June 30, 2026, and operating losses of $8.8 million for the first half, Semnur is running on fumes. The auditor's going concern warning is repeated, and material weaknesses in internal controls remain unfixed. A potential lifeline emerged on July 3, when a binding term sheet was signed for a $100 million equity investment at $10.00 per share — a massive premium to the current $0.75 stock price. If that deal closes, it would be transformative, but the term sheet is non-binding on completion and subject to due diligence. Underscoring the desperation, the company also terminated two previously announced financing deals totaling $120 million in April. Adding to the overhang, Scilex distributed 13.97 million Semnur shares to its own holders in Q2.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 39.9% of the 323 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SMNR was trading at $0.75 on OTC in the Life Sciences sector, with a market capitalization of approximately $172.7M. The 52-week trading range was $0.25 to $23.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.